

1 Today, you are being asked to take part in this **research** study because you have strabismus, 2 which is a misalignment of the eyes. Research is a study that is done to answer a question. 3 Participation in this study is voluntary. You can decide not to take part in this study at any time. 4 Your study doctor will be talking with you regarding this document. However, any of the study 5 doctors from the practice may take care of you during the study if you decide to participate. If 6 you do not clearly understand information in this document, please ask your study doctor to 7 explain. 8 9 The Pediatric Eye Disease Investigator Group is doing this study to learn how well treatments for 10 strabismus work. Your eye doctor is a member of this group. 11 12 Before you decide to take part in this research study, we encourage you to speak with friends and family members. Take your time making a decision. Carefully read this document. Your 13 14 decision will not affect your regular medical care. If you are taking part in another research 15 study, please tell your study doctor. 16 17 Important information about this study is found in this consent form. This form is part of the 18 process to inform you about the research study. 19 20 Your doctor(s) and/or clinic staff will carry out this study; see their names in the last page. 21 Funding for the study is being provided by the National Eye Institute. The institute is part of the 22 federal government. This funding will be used by the Jaeb Center for Health Research to 23 organize the research study and will be paid to your doctor's office for conducting the study. 24 25 WHY ARE WE DOING THIS STUDY? The purpose of this study is to learn about treatments for strabismus in adults. We will collect 26 27 information about many adults who receive treatment for this problem. By getting this

- 28 information, we hope to improve the care of adults with strabismus.
- 29
- 30 There are several different treatment options for strabismus. Sometimes these conditions are
- 31 treated with special glasses that help to align the eyes (prism) or with exercises that help the eyes
- 32 work together. Sometimes these conditions are treated with surgery or botox injection to
- 33 straighten the eyes. You and your eye doctor will decide which treatment you feel is the best
- 34 option for you. We encourage you to talk with your eye doctor about your treatment.
- 35





36 You and your eye doctor will decide the best treatment option for you. We encourage you to talk 37 with your eye doctor about your treatment. 38 39 HOW MANY PEOPLE ARE WE EXPECTING TAKE PART IN THIS STUDY? 40 Up to 650 people will take part in this study at several different locations throughout North 41 America. 42 43 WHAT HAPPENS IF I AGREE TO TAKE PART IN THIS STUDY? 44 To take part in the study, you will need to carefully read and sign this document. Your 45 participation is VOLUNTARY. You can decide not to take part in this study. You can decide to 46 stop your participation in this study at any time. You may continue to receive medical care not 47 related to this study. No penalty or loss of medical care will result from your decision. 48 49 To take part in this study, you must have one of the following types of strabismus: 50 51 **Convergence insufficiency** – the eyes do not turn in enough to focus together on close . 52 objects. 53 **Divergence insufficiency** – the eyes align at near, but cross slightly when viewing distant 54 objects. 55 . **Small-angle hypertropia** – one eye points slightly higher or lower than the other eye. 56 57 To take part in this study, you and your eye doctor must be ready to initiate treatment. Treatment 58 can be prism, eye exercises, botox injection, or surgery. 59 60 There are some other criteria that are necessary for you to be part of the study. Your study 61 doctor will check if you have these or not. 62 63 If you take part in the study, you must be willing to follow the procedures described below. 64 65 The study involves collecting information from your medical record. This will include the type of strabismus you have, how it is being treated, how well your eyes move and are aligned, and 66 67 how well you are able to see. We will also collect information about symptoms you may have 68 because of your strabismus and how it affects you. 69 70 You will see your doctor at 10 weeks and 1 year after starting treatment for strabismus. Your doctor may also decide that he/she will see you at other times as well. If your doctor changes 71





- you to a different treatment, you may see your doctor again at 10 weeks and 1 year after starting
- the new treatment.
- 74
- 75 In the following table you will find what will be done at each visit:

Test	Description
Diplopia Questionnaire	Evaluates how often and where you see double
Adult Strabismus 20 (AS-20) Questionnaire	Evaluates how well your eyes feel
Distance Visual Acuity	Evaluates how well you see in each eye
Ocular Alignment	Evaluates how well your eyes line up with each other
Fusion with Prism in Space	Evaluates how your eyes align together using prisms

76

77 Additional tests depend on your strabismus type.

Test	Description
If you have convergence insufficiency:	
CI Symptom Survey	Evaluates if you have symptoms of CI
Positive Fusional Vergence	Measures how well your eyes move towards each other horizontally
Near Point of Convergence	Measures how well your eyes work together up close
If you have divergence insufficiency	
Negative Fusional Vergence	Measures how well your eyes move away from each other horizontally
If you have small angle-hypertropia:	
Vertical Fusional Amplitudes	Measures how well your eye move towards each other vertically
Double Maddox Rod Testing	Determines how much your eyes are tilted with respect to each other

78

- 79 If you decide not to take part in this study and do not sign this document, you may continue
- 80 receiving medical care unrelated to this study. You can decide to stop being in the study at any
- 81 time. No penalty or loss of medical care will result if you decide not to take part in this study.
- 82

83 ARE THERE RISKS IN THIS STUDY?

- 84 If you decide to be part of the study, a possible risk is the chance that an unauthorized person
- 85 outside of the research team will see your health information. This is unlikely to happen. The
- 86 study will take special efforts to make sure this does not happen.
- 87
- 88 This form does not list risks related to your normal medical care. This form does not list risks to
 - the treatment that you and your doctor have selected. We encourage you to discuss these with
 - 90 your study doctor, your primary care provider, or another health care professional.
 - 91





92 WHAT ARE THE BENEFITS OF TAKING PART IN THIS STUDY?

- 93 You may receive no direct benefit from being in the study. People who take part in this research 94 study will add to new knowledge that may help other people with the same problems.
- 95

96 WHAT ALTERNATIVE PROCEDURES OR TREATMENT ARE AVAILABLE IF I DO 97 NOT TAKE PART IN THIS STUDY?

98 You do not need to be in this study to get treatment for strabismus. We suggest you discuss your 99 options with your study doctor, your primary care physician, or another health care professional.

100

101 WHAT IF I WANT TO WITHDRAW FROM THE STUDY, OR I AM ASKED TO 102 WITHDRAW FROM THE STUDY?

102 WITHDRAW FROM THE STUDY?

- 103 You can stop participating in this study at any time. You may continue to receive medical care
- 104 not related to this study. No penalty or loss of medical care will result from your decision.
- 105 However, we encourage you to talk to a member of the research group so that they know why
- 106 you are leaving the study. If there are any new findings during the study that may affect whether
- 107 you want to continue participating, you will be told about them.
- 108
- 109 Your participation can be stopped by your doctor. The study can be stopped by federal regulatory
- 110 agencies or the sponsor. Your permission is not required for this. Some possible reasons for this
- 111 include poor recruitment or unexpected circumstances.
- 112

113 HOW WILL MY INFORMATION BE PROTECTED AND KEPT CONFIDENTIAL?

- 114 As required by law, study related records with identifying information will be kept confidential.
- 115 Safeguards for authorized access, security, and privacy of your information have been put in
- 116 place by the Federal Privacy Regulations. Unless the law requires it, your name, address, social
- security number, telephone number, or any other direct identifying information will not be used
- 118 to identify you.
- 119

120 A. Purpose of Authorization

- 121 We have rules to protect information about you. Federal and state laws and the federal medical
- 122 Privacy Rule also protect your information. By signing this form you provide your permission,
- 123 called your "authorization," for the use and disclosure of information protected by the Privacy
- 124 Rule.
- 125
- 126 You must sign the **Protected Health Information Authorization** at the end of this form if you
- 127 want to be in the study. When you sign the form, you give permission for the use and disclosure





- 128 of your Protected Health Information (PHI) for the study. PHI is health information that
- 129 identifies you. Your authorization is beneficial and important for the study. Without your
- 130 authorization, you will not be able to be in it.
- 131

132 **B.** Use and Disclosure of the PHI

- Your study doctor will collect information about you. This information includes things learned 133
- 134 from procedures listed and described in this form as well as your name, address, date of birth,
- 135 and information from your medical records. Your name, address, telephone number, and social
- 136 security number are examples of identifiable information.
- 137
- 138 A code number will go with your study results instead of your name, address, telephone number,
- 139 or social security number. Your study results will be given to the Jaeb Center for Health
- 140 Research. The Jaeb Center is the coordinating center for the study. It is located in Tampa,
- 141 Florida.
- 142

143 This doctor's office will not disclose study results that have your identifiable information except 144 as explained in Section C. or when required by law. The Jaeb Center and this doctor's office will guard the privacy of your study PHI.

- 145
- 146

147 Study results without your protected information may appear in medical journals and be shared

- 148 at scientific meetings. Your records will be kept confidential. No one will disclose your identity
- 149 in a medical journal or at a scientific meeting.
- 150

151 **C.** Authorized Recipients and Users

- 152 People outside of this doctor's office and the Jaeb Center may need to see or receive your
- 153 information from this study. Some examples include: government agencies (such as the Food
- 154 and Drug Administration), safety monitors, other sites in the study, and companies that sponsor
- 155 the study.
- 156
- 157 In most cases the information will have a code number with it instead of your name, address,
- 158 telephone number, or social security number.
- 159
- 160 There are some situations where the information will not have a code number with it. If so,
- 161 people outside this doctor's office who assist in your care may see your study PHI. They may
- 162 not be covered by the federal Privacy Rule. We try to make sure that everyone who needs to see





- your information keeps it confidential but we cannot guarantee that your information will not
- 163 164 be disclosed.
- 165

Other Considerations 166

- 167 The data collected in the study may be provided to other researchers to use; however, the data 168 that are provided will not contain any information that could identify you.
- 169
- 170 When the results are made public, all of the study data collected may also be made public.
- 171 However, no identifying information will be included.
- 172

173 Separately from your research data, the Jaeb Center for Health Research in Tampa, Florida will 174 be provided with information on how to contact you. 175

- 176 Before your study visits you may receive a phone call from a staff member at the Jaeb 177 Center to check on your condition and to see if you have any questions. You will be 178 called at a time that you indicate is most convenient for you. If you are not available at 179 the time of the call and prefer to call the coordinating center yourself, you can call the 180 coordinating center toll-free at 1-888-797-3344.
- 181
- 182 If we are not able to locate you when we try to schedule your follow-up visit, the Jaeb 183 Center may try to contact you through the alternative contact information you have given 184 us. If this is not successful, the Jaeb Center may use the information you have given us to 185 try to locate you through the use of a third-party search service.
- 186

187 **D.** Cancellation of Authorization

- 188 You may cancel your permission for the use and disclosure of your study PHI at any time. You 189 need to contact your study doctor and give him/her a notice of cancellation in writing. When you 190 cancel your permission or when you withdraw from the study directly, you are no longer part of 191 the study. No new information about you will be gathered for the study except when it is on an
- 192 adverse (unfavorable) event that is related or potentially related to the study. If one happens, 193 your entire medical record may need to be reviewed.
- 194
- 195 The Jaeb Center will receive all the information that has already been collected for the study up
- 196 to the time of cancellation or withdrawal. Any new information about any adverse (unfavorable)
- 197 event that is related or potentially related to the study will also be sent to the Jaeb Center.
- 198





- 199 E. 50 Year Expiration Date and Indefinite Expiration Date
- 200 Some of your study PHI does not have a code number with it. Your permission for the use and
- 201 disclosure of this PHI lasts 50 years from the date of your signature or until the end of the study,
- 202 whichever is sooner.
- 203
- 204 The rest of your study PHI does have a code number with it. When it is collected, it becomes a
- 205 research report. Your permission for the use and disclosure of these coded data will never end.
- 206 These coded data do <u>not</u> have your name, address, telephone number, or social security number.
- 207 The above supports the HIPAA Privacy Rule 45 CFR 164.508
- 208

209 ARE THERE COSTS RELATED TO TAKING PART IN THE STUDY?

- 210 The study will pay for visits that are done just for the research study. The study will not pay for
- 211 usual care visits. Usual care visits are those that would occur whether or not you are in the
- study. The cost of usual care visits will be your or your insurance company's responsibility.
- 213
- The study will not pay for any costs associated with treatment. These will be your or your insurance company's responsibility.
- 216

217 IS THERE COMPENSATION FOR TAKING PART IN THIS STUDY?

- If you take part in the study, you will receive \$25 for each 10-week visit and \$50 for each 12month visit (by money card). The maximum amount you will receive will be \$150. The money
- 220 card is being given to you to cover the cost of travel and other visit related costs. You will not
- 221 receive any money for extra visits your doctor believes are needed for your usual care.
- 222
- If you have travel expenses that make it difficult for you to return for study visits, let your doctor know. Additional funds may be available.
- 225

226 WHAT HAPPENS IF I EXPERIENCE A RESEARCH RELATED INJURY?

- If you have a research-related injury, medical care is available. In case of an emergency, you can
- get emergency care. If possible, you should tell the emergency care medical staff that you are in
- a research study. You should also tell your study doctor about the emergency as soon aspossible.
- 230
- 232 The study <u>will not provide</u> costs for medical expenses or any other costs for research-related
- 233 injuries. The costs of care are your or your insurance company's responsibility. Money for lost
- 234 wages and/or direct or indirect losses is not available. You are not precluded from seeking to get





235	compensation for injury related to malpractice, fault, or blame on the part of those involved in
235	the research.
230	the research.
238	If you have questions about the study or research-related injuries, contact your eye doctor or one
239	of his/her staff (see contact information on the last page). You may also contact the PEDIG
240	Coordinating Center staff at the Jaeb Center (toll-free at 888-797-3344).
241	
242	WHO SHOULD I CONTACT, IF I SHOULD EXPERIENCE ANY PROBLEMS OR
243	HAVE ANY QUESTIONS?
244	Please contact your eye doctor or one of his/her staff (see contact information on the last page) if
245	you:
246	Have questions about this study
247	Have questions about research-related injury
248	Have concerns or suggestions
249	
250	You may also contact the PEDIG Coordinating Center staff at the Jaeb Center (toll-free at 888-
251	797-3344).
252	
253	Please contact the Jaeb Center for Health Research Institutional Review (IRB) Office at 813-
254	975-8690 or at <u>irb@jaeb.org</u> if you:
255	 Have questions about your rights as a research participant
256	Wish to talk about your concerns or suggestions linked to the research study
257	Want additional information about the research
258	Want to provide comments about the research.
259	
260	WITHDRAWAL BY INVESTIGATOR, PHYSICIAN, OR FUNDING SOURCE
261	The investigators, physicians or funding source may stop the study or take you out of the study at
262	any time should they judge that it is in your best interest to do so, if you experience a study-
263	related injury, if you need additional or different medication, or if you do not comply with the

- study plan. They may remove you from the study for various other administrative and medical 264
- reasons. They can do this without your consent. 265
- 266





	y to Act for the Subject
	(if applicable)
Protected Health Information Authorizat	<u>tion</u>
By signing, you authorize the use and dis information is collected as part of your po	closure of your protected health information. T articipation in this study.
Signature	Date
Study Enrollment	
	form about the study named below; scuss the study and to ask questions:
you have been given the chance to di	•
you have been given the chance to dis you have verbally summarized your us explaining it to you; and	scuss the study and to ask questions; nderstanding of the study to the person who is
you have been given the chance to dis you have verbally summarized your un explaining it to you; and you freely choose to participate.	scuss the study and to ask questions; nderstanding of the study to the person who is
you have been given the chance to dis you have verbally summarized your un explaining it to you; and you freely choose to participate. Name of Study: <u>A Prospective Observation</u> Signature	scuss the study and to ask questions; nderstanding of the study to the person who is onal Study of Adult Strabismus Date the participant understands the nature, demand





Consent to Participate in a Research Study A Prospective Observational Study of Adult Strabismus **Investigator Contact Information** Name of Investigators: [list all investigators at site] Address: Telephone: s page nvestigators

